Deals channel feed – Endpoints News

Deals channel feed

Dr. Reddy's to buy Mayne Pharma’s US generics drug list for at least $90M

3 years ago

Pfizer makes moves to acquire Seagen in potential $30B+ deal

3 years ago

Nektar’s latest PhII flop threatens to unravel $400M-plus deal with Eli Lilly

3 years ago

Roche and Blueprint agree to end collaboration for cancer drug Gavreto

3 years ago

February freeze hits biotech as companies cut staff, thin pipelines and merge to survive

3 years ago

Adding to Claudin18.2 portfolio, AstraZeneca pays $63M cash for antibody-drug conjugate out of China

3 years ago

Former high-flying I/O biotech shelves lead drugs, chops staff and hands off the remnants in Nasdaq reshuffle

3 years ago

Capsida and AbbVie make $70M upfront deal for genetic medicines in eye diseases

3 years ago

Kinnate engineers $24M deal to win control of China joint venture back from OrbiMed, Foresite

3 years ago

Oxford Properties Group purchases Resilience manufacturing site for $125M

3 years ago

Merck hands Swedish biotech €10M cash to develop anti-inflammatory drugs

3 years ago

Biotech consolidation continues as Nasdaq-listed Erytech merges with phage therapy developer

3 years ago

The top 100 biotech VCs: Who's staying at the table and what do they want now?

3 years ago

Updated: J&J returns rights to early-stage, RNAi NASH candidate to Arrowhead

3 years ago

Cullinan Oncology drops $25M upfront for candidate from Harbour

3 years ago

Tillman Gerngross’ Amagma Therapeutics quietly ships antibodies to another biotech

3 years ago

With record-breaking mpox vaccine sales, Bavarian Nordic buys trio of shots from Emergent for $270M cash

3 years ago

Sesen Bio reaches deal with investor group, paving way for Carisma merger

3 years ago

A Texas-based biotech becomes the latest to enter the SPAC scene

3 years ago

GSK revises Covid deal with Vir, pulls out of next-gen work

3 years ago

Oramed to review strategic alternatives, clouding path forward for oral insulin

3 years ago

The top 100 venture investors in biopharma today. Who's staying at the deals table?

3 years ago

As acquisition rumors surface, Catalent remains mum on deal

3 years ago

Dragonfly chief: Bristol Myers shouldn’t blame IL-12’s clinical performance for decision to scrap the deal — economics played a key role

3 years ago

First page Previous page 40 41 424344 45 46 Next page Last page